MedTrace Logo

Genetic Determinants of the Metabolism of Non-nucleoside Reverse Transcriptase Inhibitors

NCT00730223 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2013-02-15

No results posted yet for this study

Summary

To see if certain variations in the CYP2B6 gene contribute to differences in plasma drug levels and central nervous system side affects in people who take nevirapine or efavirenz.

Conditions

  • HIV Infections

Interventions

DRUG

Nevirapine and Efavirenz

single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz

Sponsors & Collaborators

  • Vanderbilt University

    lead OTHER

Principal Investigators

  • David W Haas, MD · Associate Professor of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-03-31
Primary Completion
2006-03-31
Completion
2009-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00730223 on ClinicalTrials.gov